Remote Ischemic Conditioning for Non-Proliferative Diabetic Retinopathy

Last updated: June 22, 2025
Sponsor: Xuxiang Zhang, MD
Overall Status: Active - Recruiting

Phase

N/A

Condition

Retina

Diabetic Vitreous Hemorrhage

Diabetes Mellitus, Type 2

Treatment

Sham Remote Ischemic Conditioning Device

Remote Ischemic Conditioning Device

Clinical Study ID

NCT06713720
CFH2024-2-20113
CFH2024-2-20113
  • Ages 40-80
  • All Genders

Study Summary

The goal of this clinical trial is to evaluate whether remote ischemic conditioning (RIC) is a safe and effective treatment for non-proliferative diabetic retinopathy (NPDR) in adults aged 40-80 years with type 2 diabetes. The study aims to address the limitations of current treatments for NPDR by using RIC, a technique involving repeated cycles of ischemia and hypoxia stimulation to activate protective mechanisms against retinal damage.

The main questions it aims to answer are:

Does RIC improve the Diabetic Retinopathy Severity Score (DRSS) after one year of treatment? Does RIC reduce the incidence of vision-threatening proliferative diabetic retinopathy (PDR)? What are the changes in retinal neurovascular unit parameters, visual acuity, and retinal oxygen saturation after RIC treatment?

Participants will:

Undergo RIC therapy using a specialized device on both upper limbs (or a placebo intervention for the control group) for 1 year.

Complete 5 cycles of RIC or placebo treatment twice daily, 5 days per week. Receive routine care for diabetic retinopathy as per clinical guidelines.

Key outcome measures:

Primary outcome: Change in DRSS from baseline after one year. Secondary outcomes: Incidence of PDR, changes in visual acuity, retinal neurovascular unit measures, retinal oxygen saturation, and serum biomarkers (e.g., VEGF, CRP, IL-6).

This randomized, double-blind, placebo-controlled trial aims to recruit 68 participants to ensure 60 complete the study, accounting for a 13% dropout rate. The findings are expected to provide insights into RIC as a novel intervention for NPDR, reducing blindness risk and supporting future large-scale trials.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age between 40 and 80 years.

  • Diagnosed with Type 2 diabetes mellitus.

  • Diagnosed with mild to moderate non-proliferative diabetic retinopathy (NPDR) with aDR Severity Score (DRSS) grade of 20-47D.

  • Capable of performing daily activities independently.

  • Willing and able to provide informed consent.

Exclusion

Exclusion Criteria:

  • Presence of diabetic macular edema (macular thickness > 250 μm).

  • Significant eye diseases affecting evaluation, such as high myopia, severe cataract,corneal leucoma, glaucoma, retinal detachment, retinal vein occlusion, congenitaleye diseases, ocular tumors, or severe infection.

  • History of ocular laser or intraocular surgery.

  • Poor imaging quality due to refractive media opacity.

  • Contraindication to fluorescein fundus angiography.

  • Unstable blood glucose (HbA1c ≥ 8.0%) despite oral antidiabetic drugs.

  • Severe diabetes complications within the past 6 months.

  • Severe, sustained hypertension (systolic ≥ 180 mmHg or diastolic ≥ 110 mmHg).

  • Body mass index (BMI) ≥ 28 kg/m².

  • Hepatic or renal insufficiency: Alanine aminotransferase or aspartateaminotransferase > 2 times the upper limit of normal. Estimated glomerularfiltration rate (eGFR) < 60 mL/min/1.73m². Urine albumin/creatinine ratio ≥ 30 mg/g.

  • Myocardial infarction within the past 6 months.

  • Neurological diseases such as Alzheimer's, Parkinson's, cerebrovascular disease,intracranial tumor, cerebrovascular malformation, or aneurysm.

  • Contraindications to RIC, including one-sided subclavian artery stenosis, upper limbinjuries or vascular diseases, or limb deformities.

  • Severe systemic diseases, such as malignant tumors with a life expectancy of lessthan 24 months.

  • Known pregnancy or breastfeeding.

  • Participation in other experimental clinical studies.

  • Any other conditions deemed unsuitable by the investigator.

Study Design

Total Participants: 68
Treatment Group(s): 2
Primary Treatment: Sham Remote Ischemic Conditioning Device
Phase:
Study Start date:
April 20, 2025
Estimated Completion Date:
May 31, 2026

Study Description

Non-proliferative diabetic retinopathy (NPDR) represents an early yet critical stage of diabetic retinopathy, a leading cause of vision loss globally. Despite advancements in medical treatments such as anti-VEGF therapy and laser photocoagulation, there remains a significant gap in safe and effective interventions to halt or reverse NPDR progression. Current therapies often focus on advanced disease stages, leaving early-stage management a challenge.

Remote ischemic conditioning (RIC) introduces a novel, non-invasive approach to NPDR treatment. Based on the concept of "fighting hypoxia with hypoxia," RIC employs intermittent cycles of ischemia and reperfusion in the limbs to trigger endogenous protective mechanisms against hypoxic damage. Experimental studies have highlighted RIC's potential benefits, including enhanced retinal oxygenation, reduced pathological vascular proliferation, and preservation of retinal ganglion cells.

This study is designed as a randomized, double-blind, placebo-controlled clinical trial to evaluate RIC's safety and efficacy in adults aged 40-80 years with mild to moderate NPDR. The trial features meticulous inclusion and exclusion criteria to ensure the reliability of findings. Participants will undergo either RIC or placebo therapy using a specialized device. The RIC group will receive therapy at 200 mmHg inflation pressure, while the placebo group will undergo sham treatment at 60 mmHg. Both treatments will follow the same cycle and frequency, ensuring blinding is maintained.

The study's outcomes include comprehensive assessments of retinal structure and function, systemic biomarkers, and safety metrics. These encompass changes in Diabetic Retinopathy Severity Score (DRSS), retinal neurovascular parameters, visual acuity, and retinal oxygenation. Serum biomarkers such as VEGF, CRP, and IL-6 will provide insights into systemic inflammatory and vascular changes post-treatment.

The findings from this trial are expected to offer preliminary evidence on RIC as a safe and effective intervention for NPDR. This work aims to lay the groundwork for future large-scale studies and provide clinicians with a potential strategy to reduce the burden of diabetic retinopathy and its associated complications.

Connect with a study center

  • Xuanwu Hospital

    Beijing, Beijing 100730
    China

    Site Not Available

  • Xuanwu Hospital, Capital Medical University

    Beijing, Beijing 100730
    China

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.